Neoantigen specific TCR-T cell drug product
TCR001-201
Phase 2 mab terminated
Quick answer
Neoantigen specific TCR-T cell drug product for Gynecologic Cancer is a Phase 2 program (mab) at Alaunos Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Alaunos Therapeutics
- Indication
- Gynecologic Cancer
- Phase
- Phase 2
- Modality
- mab
- Status
- terminated